SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders discuss potential U.S.-China trade deal impacts and the strength of big tech companies like Apple, with community members weighing in on bullish and bearish signals. Debate centers around whether recent market behavior is indicative of a healthy consolidation or a looming correction, with some expressing concerns about potential risks in AI and regional banks. News of potential interest rate cuts, rising treasury yields, and key economic data releases are adding to the conversation.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as the community discusses its recent price surge and potential for further gains, with some targeting prices such as $300 and beyond. Privacy narratives and comparisons to Bitcoin are circulating, while others speculate on market manipulation and future price corrections. Discussions also include the upcoming 9 year anniversary.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to community discussion around its low float, regained NASDAQ compliance, and a recently announced contract, drawing comparisons to other Hong Kong-based stocks that have experienced significant gains. Traders are also noting the high cost to borrow, speculating about a potential short squeeze. The company's expansion into EV infrastructure and AI-powered solutions is adding to the positive sentiment.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors discuss the potential of ivonescimab, particularly following trial data suggesting reduced cancer progression risk; the community is analyzing the drug's efficacy and overall survival benefits, while also considering potential regulatory hurdles and competition in the oncology market. Some traders point to insider buying as a bullish signal, while others express caution regarding the drug's performance in specific patient groups and the company's overall valuation. The conversation also includes speculation about potential partnerships and upcoming presentations of trial data.

SSgA Active Trust - Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The technology sector, represented by XLK, is seeing mixed signals with potential tariff implications and leadership shifts impacting market sentiment. Community discussions revolve around whether current levels can be sustained, and if a broader market pullback is on the horizon, especially given earnings results from major tech companies and conflicting reports regarding trade policies. Despite some analysts remaining bullish, concerns about the sector's future performance are being actively discussed.

Fuzzybear ($FUZZY) is a memecoin on the XRP Ledger (XRPL), created to honor the legacy of the well-known XRPL address ‘Fuzzybear,’ which famously placed a DEX order in 2014: 1 XRP for 1 BTC. The token embodies the spirit of decentralization and community-driven growth, focusing on fun, engagement, and organic expansion. With its unique narrative and strong community, Fuzzybear grows naturally as more supporters join the movement.

Fuzzybear

Fuzzybear ($FUZZY) is trending as community members highlight its connection to XRP and potential role within the XRP Ledger ecosystem, with some suggesting it could be the next big memecoin. Discussions also mention an upcoming event and the potential for exchange listings, fueling speculation and interest. Community members also note that David Schwartz, Ripple's CTO, recently joined a discussion about Fuzzybear on X.

Towns

$TOWNS is trending as community members actively discuss recent price movements and encourage others to join. Some users highlight potential for significant gains, while others speculate about exchange listings and future developments. The community references other trending tickers and possible connections to external entities, contributing to the heightened interest.

Alchemy Pay

Alchemy Pay is trending due to discussions around potential partnerships, developments in stablecoin integration, and speculation about future price movements. Community members are actively debating its utility, price predictions, and whether it will follow the performance of other cryptocurrencies. The focus seems to be on Alchemy Pay's role in facilitating fiat-to-crypto transactions and its potential for growth in the evolving digital payment landscape.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is garnering attention as community members discuss its potential, partnerships, and valuation relative to competitors like Progressive. Conversations revolve around whether the company can translate partnerships into substantial growth and if upcoming earnings will reflect this. Despite recent price declines, some investors remain optimistic, viewing it as an undervalued opportunity with long-term potential akin to early-stage Tesla or Hood.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics ($CORT) is trending due to positive Phase 3 ROSELLA trial results showing improved progression-free survival for patients with platinum-resistant ovarian cancer, sparking investor optimism. The community is discussing the potential for relacorilant to become a new standard of care and its impact on the company's growth. Broader interest may also stem from Corcept's pipeline and focus on endocrinologic, oncologic, metabolic and neurologic disorders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.

Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?

CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of +26.09% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CORT News

CORTCorcept Therapeutics Inc